Introducing way more signals! We've added more signal sources to capture the full customer journey.

Learn More!
Cell Cure Neurosciences

Cell Cure Neurosciences

Cell Cure Neurosciences Ltd. was established in 2005 as a subsidiary of ES Cell International Pte. Ltd. (ESI), now a subsidiary of BioTime, Inc. Cell Cure is located in Jerusalem, Israel on the campus of Hadassah University Hospital. Cell Cure's mission is to become a leading supplier of human embryonic stem cell-based therapies for the treatment of retinal and neural degenerative diseases. Its technology platform is based on the manufacture of diverse cell products sourced from clinical-grade (GMP) human embryonic stem cells. Its current focus is the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. Cell Cure's major shareholders include BioTime, Inc., Hadasit BioHoldings Ltd. (Tel Aviv Stock Exchange: HDST), and Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA).

Last updated on

About Cell Cure Neurosciences

Founded

2008

Estimated Revenue

$1M-$10M

Employees

11-50

Funding / Mkt. Cap

$2M

Category

Industry

Biotechnology

Location

City

Jerusalem

State

Jerusalem

Country

Israel
Cell Cure Neurosciences

Cell Cure Neurosciences

Find your buyer within Cell Cure Neurosciences

Tech Stack (0)

search